Voyager Therapeutics, Inc. (VYGR)
| Market Cap | 225.88M +31.6% |
| Revenue (ttm) | 40.37M -49.5% |
| Net Income | -119.72M |
| EPS | -2.04 |
| Shares Out | 59.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 583,456 |
| Open | 4.010 |
| Previous Close | 4.040 |
| Day's Range | 3.780 - 4.020 |
| 52-Week Range | 2.645 - 5.550 |
| Beta | 1.38 |
| Analysts | Strong Buy |
| Price Target | 16.50 (+335.36%) |
| Earnings Date | May 8, 2026 |
About VYGR
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease. The company also provides research program for the treatment of Huntington’s disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small mo... [Read more]
Financial Performance
In 2025, Voyager Therapeutics's revenue was $40.37 million, a decrease of -49.53% compared to the previous year's $80.00 million. Losses were -$119.72 million, 84.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for VYGR stock is "Strong Buy." The 12-month stock price target is $16.5, which is an increase of 335.36% from the latest price.
News
Voyager Therapeutics Transcript: Stifel 2026 Virtual CNS Forum
2026 is positioned as a pivotal year with major tau-targeted programs advancing, including gene therapy and antibody assets, and the first clinical use of BBB-penetrant capsids. Key data readouts and expanded partnerships are expected to drive progress in neurodegenerative disease innovation.
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies...
Voyager Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Three strategic pillars—tau-targeting, gene therapy, and NeuroShuttle—drive innovation, with two gene therapies entering the clinic and strong financial runway. Tau PET imaging is central to clinical development, and partnerships are key for advancing large-scale Alzheimer's trials.
Voyager to Present at Upcoming Investor Conferences
LEXINGTON, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced ...
Voyager Therapeutics Transcript: Stifel 2025 Healthcare Conference
The company is advancing a multimodal neurotherapeutics pipeline, with a strong focus on Alzheimer's and Tau-targeted therapies, including gene therapy and antibody programs. Key assets are progressing toward clinical readouts, and strategic partnerships support expansion into additional neurodegenerative and rare disease indications.
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging biomol...
Voyager Reports Third Quarter 2025 Financial and Operating Results
- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery progr...
Voyager Therapeutics Transcript: Baird Global Healthcare Conference 2025
The session highlighted a multimodal neurotherapeutics strategy, with a focus on Alzheimer's and Tau-targeted programs, including a pathologic-specific antibody and gene therapy entering the clinic next year. NeuroShuttle and ALPL shuttles show promise, and strong partnerships plus a $262M cash runway support upcoming milestones.
Voyager Therapeutics Transcript: Citi's Biopharma Back to School Conference
The company is advancing a robust neurotherapeutics pipeline, with four clinical programs expected by 2026 and a focus on validated CNS targets. Its Neuro Shuttle platform, highlighted by ALPL receptor data, aims to optimize brain delivery for diverse modalities. Cash runway extends into 2028, supporting ongoing clinical and partnered programs.
Voyager Reports Second Quarter 2025 Financial and Operating Results
- Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer's disease franchise - - ...
Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant -
Voyager Therapeutics Transcript: H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
The conference showcased advances in CNS drug development, with a focus on multi-modality approaches and innovative delivery platforms. Key Alzheimer’s programs target tau with both antibody and gene therapy, and major partnerships are driving near-term milestones and financial strength.
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced ...
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication
LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced t...
Voyager Reports First Quarter 2025 Financial and Operating Results
– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg –
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting
- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg -
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical mu...
Voyager Therapeutics Transcript: Virtual CNS Forum
The panel highlighted advances in neurotherapeutics, including novel AAV capsid platforms, tau-targeting programs, and emerging drug delivery strategies. Key milestones include upcoming INDs for partnered programs and a clinical proof of concept for the anti-tau antibody expected in 2026.
Voyager Therapeutics Earnings Call Transcript: Q4 2024
Strong year-end cash of $332M and $8.2B in potential milestones support a robust pipeline, with key tau-targeting programs advancing and multiple clinical readouts expected in 2025-2026. Partnerships and innovative CNS delivery platforms remain central to growth.
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 -
Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast
LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fo...
Voyager Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference
Recent data show the anti-tau antibody program advancing with strong safety and PK, and a MAD study in Alzheimer's underway. Strategic partnerships and novel capsid technology drive value, with a robust cash runway and multiple programs targeting high unmet needs.
Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease
- Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profile -
The Schall Law Firm Invites Shareholders With Losses In Voyager Therapeutics, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Ther...
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
LEXINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company w...